Silvia Castelletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2247539/publications.pdf

Version: 2024-02-01

218677 214800 2,397 75 26 47 citations h-index g-index papers 77 77 77 3613 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
2	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	210
3	Spectrum and Prevalence of Mutations Involving BrS1-Through BrS12-Susceptibility Genes in a Cohort of Unrelated Patients Referred for Brugada Syndrome Genetic Testing. Journal of the American College of Cardiology, 2012, 60, 1410-1418.	2.8	193
4	Automatic Measurement of the MyocardialÂInterstitium. JACC: Cardiovascular Imaging, 2016, 9, 54-63.	5.3	127
5	Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study. Journal of Magnetic Resonance Imaging, 2017, 45, 1055-1067.	3.4	82
6	Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 1707-1708.	2.8	78
7	Mexiletine Shortens the QT Interval in Patients With Potassium Channel–Mediated Type 2 Long QT Syndrome. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007280.	4.8	74
8	Desmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: Genotype-phenotype correlation. International Journal of Cardiology, 2017, 249, 268-273.	1.7	70
9	Myocardial T1 Mapping. Circulation Journal, 2015, 79, 487-494.	1.6	69
10	From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. European Heart Journal, 2019, 40, 1832-1836.	2.2	69
11	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 300, 191-195.	1.7	60
12	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. Genetics in Medicine, 2021, 23, 47-58.	2.4	57
13	A wearable remote monitoring system for the identification of subjects with a prolonged QT interval or at risk for drug-induced long QT syndrome. International Journal of Cardiology, 2018, 266, 89-94.	1.7	53
14	Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace, 2021, 23, 147-148.	1.7	47
15	The genetics underlying idiopathic ventricular fibrillation: A special role for catecholaminergic polymorphic ventricular tachycardia?. International Journal of Cardiology, 2018, 250, 139-145.	1.7	42
16	Lossâ€ofâ€function desmoplakin I and II mutations underlie dominant arrhythmogenic cardiomyopathy with a hair and skin phenotype. British Journal of Dermatology, 2019, 180, 1114-1122.	1.5	41
17	<i>SCN5A</i> Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in <i>SCN5A</i> Families. Circulation Genomic and Precision Medicine, 2020, 13, e002911.	3.6	41
18	Texture analysis of cardiovascular magnetic resonance cine images differentiates aetiologies of left ventricular hypertrophy. Clinical Radiology, 2019, 74, 140-149.	1.1	39

#	Article	IF	CITATIONS
19	Late gadolinium enhancement in Brugada syndrome: A marker for subtle underlying cardiomyopathy?. Heart Rhythm, 2017, 14, 583-589.	0.7	38
20	Left Ventricular Hypertrophy Revisited. Circulation, 2017, 136, 2519-2521.	1.6	37
21	Exercise Training-Induced Repolarization Abnormalities Masquerading as Congenital Long QT Syndrome. Circulation, 2020, 142, 2405-2415.	1.6	36
22	Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). International Journal of Cardiology, 2022, 357, 55-71.	1.7	36
23	Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: Results from a multicenter study. Heart Rhythm, 2019, 16, 536-543.	0.7	35
24	Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease. Circulation: Cardiovascular Imaging, 2020, 13, e010171.	2.6	35
25	A comprehensive electrocardiographic, molecular, and echocardiographic study of Brugada syndrome: Validation of the 2013 diagnostic criteria. Heart Rhythm, 2014, 11, 1176-1183.	0.7	32
26	Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping. European Heart Journal Cardiovascular Imaging, 2017, 18, 1034-1040.	1,2	31
27	COVID-19 and Cardiovascular Disease: a Global Perspective. Current Cardiology Reports, 2021, 23, 135.	2.9	27
28	Clinical recommendations of cardiac magnetic resonance, Part I. Journal of Cardiovascular Medicine, 2017, 18, 197-208.	1.5	26
29	Appropriate use criteria for cardiovascular magnetic resonance imaging (CMR): SICâ€"SIRM position paper part 1 (ischemic and congenital heart diseases, cardio-oncology, cardiac masses and heart) Tj ETQq1 1 0.78	84 21 4 rgE	BT Ø verlock
30	Mutation location and $\langle i \rangle \langle i \rangle$ ÂKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. European Heart Journal, 2021, 42, 4743-4755.	2.2	26
31	Left Cardiac Sympathetic Denervation for Long QT Syndrome. JACC: Clinical Electrophysiology, 2022, 8, 281-294.	3.2	25
32	Clinical recommendations of cardiac magnetic resonance, Part II. Journal of Cardiovascular Medicine, 2017, 18, 209-222.	1.5	22
33	Diagnosis and management of hypertrophic cardiomyopathy. Journal of Animal Science and Technology, 2015, 2, R45-R53.	2.5	21
34	Electrocardiographic differentiation of idiopathic right ventricular outflow tract ectopy from early arrhythmogenic right ventricular cardiomyopathy. Europace, 2017, 19, euw018.	1.7	20
35	Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 64.	3.3	19
36	Clinical application of CMR in cardiomyopathies: evolving concepts and techniques. Heart Failure Reviews, 2023, 28, 77-95.	3.9	19

3

#	Article	IF	CITATIONS
37	Epicardial myocardial strain abnormalities may identify the earliest stages of arrhythmogenic cardiomyopathy. International Journal of Cardiovascular Imaging, 2016, 32, 593-601.	1.5	18
38	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	3.0	16
39	Gender Differences in International Cardiology Guideline Authorship: A Comparison of the US, Canadian, and European Cardiology Guidelines From 2006 to 2020. Journal of the American Heart Association, 2022, 11, e024249.	3.7	16
40	The ventricular ectopic QRS interval (VEQSI): Diagnosis of arrhythmogenic right ventricular cardiomyopathy in patients with incomplete disease expression. Heart Rhythm, 2016, 13, 1504-1512.	0.7	13
41	Abnormal myocardial expression of SAP97 is associated with arrhythmogenic risk. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1357-H1370.	3.2	13
42	A Shift on the Front Line. New England Journal of Medicine, 2020, 382, e83.	27.0	13
43	Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics. International Journal of Cardiology, 2019, 286, 99-103.	1.7	10
44	Diagnostic clues for the diagnosis of nonsarcomeric hypertrophic cardiomyopathy (Phenocopies): Amyloidosis, fabry disease, and mitochondrial disease. Journal of Cardiovascular Echography, 2018, 28, 120.	0.4	10
45	Appropriate use criteria for cardiovascular MRI: SIC – SIRM position paper Part 2 (myocarditis,) Tj ETQq1 1 0.784 2021, 22, 515-529.	1314 rgBT 1.5	/Overlock 9
46	The Female Athlete's Heart: Overview and Management of Cardiovascular Diseases. European Cardiology Review, 2021, 16, e47.	2.2	9
47	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. International Journal of Cardiology, 2019, 290, 100-105.	1.7	8
48	Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease. Acta Myologica, 2017, 36, 135-150.	1.5	8
49	Remote Monitoring of the QT Interval and Emerging Indications for Arrhythmia Prevention. Cardiac Electrophysiology Clinics, 2021, 13, 523-530.	1.7	7
50	Generation of the human induced pluripotent stem cell (hiPSC) line PSMi003-A from a patient affected by an autosomal recessive form of Long QT Syndrome type 1. Stem Cell Research, 2018, 29, 170-173.	0.7	6
51	Hypertrophic cardiomyopathy: insights from extracellular volume mapping. European Journal of Preventive Cardiology, 2022, 28, e39-e41.	1.8	6
52	Molecular genetic testing in athletes: Why and when a position statement from the Italian Society of Sports Cardiology. International Journal of Cardiology, 2022, 364, 169-177.	1.7	6
53	Management of nonischemic-dilated cardiomyopathies in clinical practice: a position paper of the working group on myocardial and pericardial diseases of Italian Society of Cardiology. Journal of Cardiovascular Medicine, 2020, 21, 927-943.	1.5	5
54	Dietary components and risk of cardiovascular disease and all-cause mortality: A review under the sign of the carrot. European Journal of Preventive Cardiology, 2019, 26, 1412-1414.	1.8	4

#	Article	IF	Citations
55	Sports cardiology in Europe from the ancient Greek-Roman era to the present. European Heart Journal, 2022, 43, 2542-2544.	2.2	4
56	The Young Community of the European Association of Preventive Cardiology: The future in motion. European Journal of Preventive Cardiology, 2018, 25, 567-568.	1.8	3
57	Partial Pericardial Agenesis Mimicking Arrhythmogenic Right Ventricular Cardiomyopathy. Clinical Journal of Sport Medicine, 2020, 30, e159-e162.	1.8	3
58	Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, O4.	3.3	2
59	Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening. Journal of Cardiovascular Medicine, 2021, 22, 759-766.	1.5	2
60	Evolution in Managing Long QT Syndrome. Journal of the American College of Cardiology, 2017, 70, 463-465.	2.8	1
61	Cardiology in 280 characters. European Heart Journal, 2022, 43, 1186-1188.	2.2	1
62	Effective Study: Development and Application of a Questionâ€Driven, Timeâ€Effective Cardiac Magnetic Resonance Scanning Protocol. Journal of the American Heart Association, 2022, 11, e022605.	3.7	1
63	The athlete's heart from Philippides to the modern marathon runners. European Heart Journal, 2022, 43, 2538-2541.	2.2	1
64	Cardiovascular magnetic resonance in hypertrophic cardiomyopathy and infiltrative cardiomyopathy. South African Journal of Radiology, 2016, 20, .	0.3	0
65	Advanced Arrhythmogenic Cardiomyopathy in Former Marathon Runner. Circulation: Cardiovascular Imaging, 2018, 11, e008204.	2.6	0
66	Long and Short QT Syndromes. Cardiac and Vascular Biology, 2018, , 147-185.	0.2	O
67	EuroPrevent 2018, cardiovascular prevention at its highest levels. European Journal of Preventive Cardiology, 2018, 25, 1127-1130.	1.8	0
68	European Journal of Preventive Cardiology. European Heart Journal, 2019, 40, 2478-2478.	2.2	0
69	The Membership Committee of the ESC. Cardiovascular Research, 2019, 115, e130-e132.	3.8	0
70	From the last EuroPrevent towards the first ESC Preventive Cardiology Congress. European Journal of Preventive Cardiology, 2019, 26, 1408-1411.	1.8	0
71	To be, or not to be engaged in sport activities, that is the amletic question for patients with coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 767-769.	1.8	0
72	Promoting Prevention: A Call for Action. European Heart Journal, 2020, 41, 3292-3294.	2.2	0

SILVIA CASTELLETTI

#	Article	IF	CITATIONS
73	Fear of Sudden Death During Sport Activity and the Long QT Syndrome. , 2022, , 127-137.		O
74	Specific Cardiovascular Diseases and Competitive Sports Participation: Channelopathies. , 2020, , 361-402.		0
75	Mitral valve prolapse and sport: how much prolapse is too prolapsing?. European Journal of Preventive Cardiology, 2021, 28, 1100-1101.	1.8	O